International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).

被引：1
|
作者：
Quinn, David I.
Baudin, Eric
Demeure, Michael J.
Fassnacht, Martin
Hammer, Gary D.
Poondru, Srinivasu
Fleege, Tanya
Rorig, Ramona
Berruti, Alfredo
机构：
[1] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[2] Inst Gustave Roussy, Villejuif, France
[3] TGen, Phoenix, AZ USA
[4] Univ Hosp Wuerzburg, Dept Internal Med 1, Endocrine Unit, Wurzburg, Germany
[5] Univ Michigan, Ann Arbor, MI 48109 USA
[6] APGD, Northbrook, IL USA
[7] Astellas Pharma Global Dev, Northbrook, IL USA
[8] Astellas Pharma, Northbrook, IL USA
[9] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Med Oncol, Brescia, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.4507
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4507
引用
收藏
页数：1
相关论文
共 50 条
  • [1] International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Linsitinib (OSI-906, L) in Patients (pts) with Locally Advanced or Metastatic Adrenocortical Carcinoma (ACC)
    Fassnacht, Martin
    Baudin, Eric
    Demeure, Michael J.
    Fleege, Tanya
    Poondru, Srinivasu
    Quinn, David I.
    Rorig, Ramona
    Hammer, Gary D.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [2] Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
    Fassnacht, Martin
    Berruti, Alfredo
    Baudin, Eric
    Demeure, Michael J.
    Gilbert, Jill
    Haak, Harm
    Kroiss, Matthias
    Quinn, David I.
    Hesseltine, Elizabeth
    Ronchi, Cristina L.
    Terzolo, Massimo
    Choueiri, Toni K.
    Poondru, Srinivasu
    Fleege, Tanya
    Rorig, Ramona
    Chen, Jihong
    Stephens, Andrew W.
    Worden, Francis
    Hammer, Gary D.
    LANCET ONCOLOGY, 2015, 16 (04): : 426 - 435
  • [3] RENAVIV: A randomized phase III, double-blind, placebo-controlled study of pazopanib with or without abexinostat in patients with locally advanced or metastatic renal cell carcinoma.
    Aggarwal, Rahul Raj
    Thomas, Scott
    Hauke, Ralph J.
    Nordquist, Luke T.
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Anlotinib treatment in locally advanced or metastatic medullary thyroid carcinoma: A multicenter, randomized, double-blind, placebo-controlled phase IIB trial.
    Li, Dapeng
    Tang, Ping Zhang
    Chen, Xiaohong
    Ge, Minghua
    Zhang, Yuan
    Guo, Zhuming
    Wang, Jun
    Shi, Feng
    Zhang, Jiewu
    Cheng, Ying
    Li, Zhendong
    Liu, Hui
    Qin, Jianwu
    Huang, Rui
    Cheng, Ruochuan
    Xu, Zhengang
    Chi, Yihebali
    Zheng, Xiangqian
    Gao, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
    Hsu, Chiun
    Yang, Tsai-Sheng
    Huo, Teh-Ia
    Hsieh, Ruey-Kuen
    Yu, Chih-Wei
    Hwang, Wei-Shou
    Hsieh, Tsai-Yuan
    Huang, Wen-Tsung
    Chao, Yee
    Meng, Robin
    Cheng, Ann-Lii
    JOURNAL OF HEPATOLOGY, 2012, 56 (05) : 1097 - 1103
  • [6] Lanreotide in Patients with Lung Neuroendocrine Tumors: The Randomized Double-Blind Placebo-Controlled International Phase 3 SPINET Study
    Reidy-Lagunes, Diane
    Kulke, Michael
    Wolin, Edward
    Singh, Simron
    Ferone, Diego
    Hoersch, Dieter
    Mirakhur, Beloo
    Hoffmanns, Philipp
    Houchard, Aude
    Caplin, Martyn
    Baudin, Eric
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1516 - S1517
  • [7] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF AMG 386 PLUS WEEKLY PACLITAXEL IN PATIENTS (PTS) WITH ADVANCED OVARIAN CANCER
    Vergote, I. B.
    Oza, A. M.
    Hansen, V. L.
    Richardson, G. E.
    Provencher, D. M.
    Ghatage, P.
    Tassoudji, M.
    Sun, Y.
    Stepan, D. E.
    Karlan, B. Y.
    ANNALS OF ONCOLOGY, 2010, 21 : 305 - 306
  • [8] A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN
    Wang, Luhua
    Chen, Ming
    Kato, Ken
    Wyrwicz, Lucjan
    Smyth, Elizabeth Catherine
    Jiang, Anastasia
    Zhang, Di
    Robbins, Scott H.
    He, Philip
    Negro, Alejandra
    Saba, Nabil F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma
    Karlan, B. Y.
    Oza, A. M.
    Hansen, V. L.
    Richardson, G. E.
    Provencher, D. M.
    Ghatage, P.
    Tassoudji, M.
    Stepan, D. E.
    Weinreich, D. M.
    Vergote, I. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Daridorexant in Japanese patients with insomnia disorder: A phase 3, randomized, double-blind, placebo-controlled study
    Uchimura, Naohisa
    Taniguchi, Mitsutaka
    Ariyoshi, Yu
    Oka, Yasunori
    Togo, Osamu
    Uchiyama, Makoto
    SLEEP MEDICINE, 2024, 122 : 27 - 34
12345